215 results about "Memory impairment" patented technology

This invention relates to the field of therapeutic agents for the treatment of Age-Associated Memory Impairment (AAMI). In particular, the present invention utilizes compositions comprising at least one compound capable of elevating ketone body concentrations in a mammal (e.g., ketogenic compounds), administered in an amount effective for treatment or prevention of loss of cognitive function caused by reduced neuronal metabolism in AAMI. In one embodiment, the composition includes medium chain triglycerides (MCT). In another embodiment, the compositions are administered in the presence of carbohydrate. The present invention also relates to oral dosage forms, in particular, a nutritional drink comprising at least one compound capable of elevating ketone body concentrations in a mammal.

The invention relates to methods of administering pharmaceutical compositions and dosage forms comprising the sertindole derivatives nor-sertindole, 5-oxo-sertindole, dehydro-sertindole, and dehydro-nor-sertindol. The methods of the invention are directed to the treatment and prevention of neuroleptic and related disorders such as, psychotic disorders, depression, anxiety, substance addiction, memory impairment and pain.

The invention belongs to the field of pharmacy, and relates to application of a hydrogen sulfide donor to the preparation of a medicine for treating central nervous system disease, in particular to application of the hydrogen sulfide donor, namely sodium hydrosulfide, or allyl cysteine and analogues thereof to the preparation of the medicine for treating the central nervous system disease. Integral animal model experiments prove that the sodium hydrosulfide and propargyl cysteine can reduce the learning and memory impairment of rats, increase the content of hydrogen sulfide in hippocampus tissues of the rats, inhibit the messenger ribonucleic acid (mRNA) expression of a tumor necrosis factor alpha and a receptor I thereof, inhibit an inflammatory mediator in the hippocampus tissues of rats with dementia and inhibit inflammation-related enzymes in the hippocampus tissues of the rats, and can be used as a medicine for treating Alzheimer disease and other inflammation-related central nervous system degenerative diseases such as Parkinson disease.

The invention thus pertains to the use of a composition comprising: (a) uridine or uridine phosphate; and (b) docosahexaenoic acid and/or eicosapentaenoic acid, for improving memory and/or the treatment or prevention of impaired memory function, in a subject with a mini-mental state examination of 24-26, wherein said composition is enterally administered to the subject. In the MMSE test, any score of 27 or higher (out of 30) is effectively normal. In the patients with dementia, 20-26 indicates mild dementia, 10-19 moderate dementia, and below 10 severe dementia. It was the present inventors' belief that within the group of 20-26, the memory impairment in the sub-group of 24-26 may even be reversible, as the pathological pathways have just started to develop. In this group of subjects the pathological pathways have just started to develop. Clinical studies show excellent results for this subgroup.

The present invention relates generally to novel hydantoin derivative compounds, pharmaceutical compositions containing such compounds, and methods for their use in preventing and/or treating neurological disorders, including physically damaged nerves and neurodegenerative diseases; for treating alopecia and promoting hair growth; for treating vision disorders and/or improving vision; for treating memory impairment and/or enhancing memory performance; and for treating sensorineural hearing loss by administering such compounds.

An alkyl ether derivative represented by the formula:

wherein R¹, R², R³, R⁴, m and n are as defined in the specification, or salts thereof exhibits synergistically improved anti-hypoxic activity when combined with a compound having an acetylcholine esterase inhibitory activity. Therefore, the combination according to the present invention is useful as a method for improving cerebral function. Further, a pharmaceutical composition containing the compound relating to the combination according to the present invention is useful for treatment and prevention of dysfunction of cerebral acetylcholine neurons in the sequelae of cerebrovascular dementia, senile dementia, Alzheimer's disease and ischemic cerebral lesion and in the cerebral apoplexy or the memory impairment caused by selective neuronal death.

This invention relates to a method for increasing the usefulness, sensitivity and specificity of tests that measure memory and facets of memory, including learning, retention, recall and/or recognition. Specifically, the sensitivity and specificity of such tests are enhanced by selectively weighting the value of specific items recalled by the test subject, either by weighting such items within any specific testing trial or across numerous testing trials. Also disclosed are various methods of reducing ceiling effects in memory tests. The invention also provides improved tests which employ item-specific weighting for the diagnosis of Alzheimer's Disease and other dementia characterized by memory impairment, as well as a method of screening for and evaluating the efficacy of potential therapeutics directed to the treatment of such dementia.

A computer based method and system forms measurements of brain function and predictions of a likelihood for memory impairment via the use of cameras, including a near-infrared (NIR) spectroscopic device and a camera capturing images in the Red-Green-Blue (RGB) spectrum. The device acquires from a subject measurements of ions, molecules, or combinations thereof at more than one moment in time, as well as amplitude and timing of blood pulsations. Based on the measured molecule or ion concentration, flow, and so forth, a processor assesses the probability of a neuron to form an action potential. Formation of an action potential increases the probability that the subject individual will create a memory.

The present invention comprises the use of pharmaceutical compositions that are effective in the inhibition of the Na⁺/H⁺ exchanger, subtype 5 (NHE-5) as inhibitors of cellular NHE-5 enhance long term potentiation (LTP) and are therefore effective in the treatment of memory impairments, dementing disorders, and for improving memory. Particularly suitable for the treatment of neurodegenerative disorders, memory impairments and dementing disorders, and for improving memory, are the following NHE-5 inhibitors of the formula I

Wherein the R1-R8 substituents are further defined herein:

The present invention provides a novel method for preventing and treating memory and cognitive impairment resulting from oxidative stress, inflammation and the process of aging, as well as, neurodegenerative conditions. The method is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants to a host in need thereof. The present also includes a novel method for simultaneously inhibiting expression of pro-inflammatory cytokines, preventing ROS generation and augmenting anti-oxidant defenses. The activity of this composition is conducive to ultimately preserving cognitive function and providing a level of neuroprotection.

This invention relates to pharmaceutical compositions and methods for treating a vision disorder, improving vision, treating memory impairment, or enhancing memory performance using pyrrolidine derivatives.

The invention provides a method for preparing Oxiracetam, which comprises the following steps: performing alkaline treatment of 4-hydroxy-2-pyrrolidone under a water-free condition; reacting the treated 4-hydroxy-2-pyrrolidone with 2-chloroacetamide in an organic solvent in the presence of a catalyst; and after the reaction is finished, performing filtration, distillation and recrystallization to obtain the Oxiracetam. In the method, the final product can be obtained by a one-step reaction, the operation is simple and convenient, and large scale production can be realized. The invention also provides the Oxiracetam obtained by the method, which has the characteristics of high yield, high purity and good treatment effect. The invention also provides the use of the Oxiracetam obtained by the method in the preparation of medicaments for treating brain dysfunction, impaired memory and senile dementia.

The present invention provides compounds of the general formula (I)

wherein X, n and R¹ are as described herein, as well as pharmaceutically acceptable salts and esters thereof, methods for their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are dual modulators of the serotonin 5-HT_2a and dopamine D₃ receptors, useful in the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.

The present invention relates to a health care wine, in particular to a health care wire which contains the traditional Chinese medicine for nourishing yin, the existing health care wines are mostly the wines for strengthening yang, which can cause the imbalance between yin and yang by excessive drinking; China has a word that yang mainly controls the organs and yin mainly controls body fluids, the excess of yang often causes qi stagnation and blood stasis, so as to cause cardiovascular diseases, hearing loss, memory impairment and alopecia. The components of the present invention include: beverage wine, each 1000 parts by weight of the beverage wine is added with 30 parts of radix rehmanniae glutinosae, 30 parts of radix rehmanniae preparata, 20 parts of common yam rhizome, 20 parts of common macrocarpium fruit, 20 parts of barbary wolfberry fruit, 15 parts of glossy privet fruit, 15 parts of tree peony bark, 20 parts of hawthorn fruit, 30 parts of tuber fleeceflower root, 30 parts of salvia, 30 parts of membranous milkvetch root, 20 parts of Chinese magnoliavine fruit, 15 parts of oriental waterplantain rhizome, 15 parts of Indian buead and 15 parts of kudzuvine root, and all the components are soaked for 25 to 40 days and then the wastes are removed. The product can be used as the health care wine for the treatment of age related hearing loss, alopecia, bad memory and the improvement of the cardiovascular adverse states.

Bombesin receptor antagonists are provided which are compounds of formula (I) or pharmaceutically acceptable salts thereof: wherein j, k, l, m, n, q, r, Ar, Ar<1>, R<1>, R<2>, R<3>, R<4>, R<5>, R<6 >and X are as defined in the description. The compounds of the invention have an affinity for the BB1 receptor and some of them also have affinity for the BB2 receptor. Accordingly they may be useful for the diagnosis, prevention, or treatment of male and female sexual dysfunction. They can also be used in the diagnosis, prevention or treatment of anxiety and panic disorders, social phobia, depression, psychoses, sleeping disorders, memory impairment, pulmonary hypertension, lung repair and lung development disorders, cancer including prostate cancer and pancreatic cancer, hepatic porphyria, gastrointestinal secretory disturbances, gastrointestinal disorders including colitis, Crohn's disease and inflammatory bowel disease, emesis, anorexia, pain, seasonal affective disorders, feeding disorders or pruritus.

An agent for improving depression-like symptoms comprising D-ribose, which may improve an alleviate various symptoms such as hypobulia, general fatigue, sluggishness, enervation, deterioration in concentration, memory impairment, abnormal sensation/obtundation such as impaired sight, decline in thinking power, indefinite complaint, drop in operation efficiency, or feeling of malaise, etc.